The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

Powles, Thomas; Blank, Christian U.; Chowdhury, Simon; Horenblas, Simon; Peters, John; Shamash, Jonathan; Sarwar, Naveed; Boleti, Ekaterini; Sahdev, Anju; O’Brien, Tim; Berney, Daniel M.; Beltrán, Luis; Nathan, Paul; Haanen, John B.A.G.; Bex, Axel

doi:10.1016/j.eururo.2011.05.028

Cited by 108 publications

(76 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, in some cases, delayed nephrectomy could probably be a good option. Apart from the theoretical advantage of downsizing of the primary renal tumor, which seems to be quite modest (2%-6% by the RECIST criteria) and probably does not facilitate surgery [27][28][29], the major concern is to quickly start effective systemic therapy without the delay associated with planning, performing, and recovering from nephrectomy. Moreover, patients with primary refractory disease would be accurately identified and therefore might have an opportunity to promptly switch to another targeted agent.…”

Section: Discussionmentioning

confidence: 99%

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Mathiéu

Pignot

Ingles

et al. 2015

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Mathiéu

Pignot

Ingles

et al. 2015

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

“…These patients had a poor outcome irrespective of whether they had surgery (median overall survival <6 months, eFigure 2). Previous retrospective analysis of other smaller prospective series with sunitinib suggested that nephrectomy was not recommended in this setting 4,15 . Our data supports this recommendation with the most robust data to date.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Powles and colleagues investigated the outcomes of 66 patients with mRCC who received preoperative sunitinib for 2-3 cycles (4 weeks on, 2 weeks off) [Powles et al 2011a]. Overall, the median reduction in the longest diameter of primary tumor was 13%.…”

Section: Tumor Downsizingmentioning

confidence: 99%

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma

Borregales

Adibi

Thomas

et al. 2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Abstract:In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have been reported with the use of targeted therapy agents, including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), mammalian target of rapamycin (mTOR) inhibitors (everolimus and temsirolimus) and VEGF receptor antibodies (bevacizumab). Current guidelines reflect these new therapeutic approaches with treatments based on risk category, histology and line of therapy in the metastatic setting. However, while radical nephrectomy remains the standard of care for locally advanced RCC, the migration and use of these agents from salvage to the neoadjuvant setting for large unresectable masses, high-level venous tumor thrombus involvement, and patients with imperative indications for nephron sparing has been increasingly described in the literature. Several trials have recently been published and some are still recruiting patients in the neoadjuvant setting. While the results of these trials will inform and guide the use of these agents in the neoadjuvant setting, there still remains a considerable lack of consensus in the literature regarding the effectiveness, safety and clinical utility of neoadjuvant therapy. The goal of this review is to shed light on the current body of evidence with regards to the use of neoadjuvant treatments in the setting of locally advanced RCC.

show abstract

The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

Cited by 108 publications

References 19 publications

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma

Contact Info

Product

Resources

About